Joshua Shipley, MD
Hematology & Oncology · Hanover, PANPI 1548487085
Payments from drug & device makers
What this record shows
This record is dominated by education: $404 of the $670 with a category attached, or 60.2%. 7 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 47.5% of the total. Reporting peaked in 2021 at $339 and has fallen 70.7% since, to $99 in 2023. That places this record below the midpoint for hematology & oncology clinicians in PA, where the typical reported total is $1,277.
Across 14 payments — averaging $47.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$319
- Sanofi$114
- Mirati Therapeutics, Inc.$99
- Johnson & Johnson$85
- Daiichi Sankyo Inc.$21
- Pharmacyclics LLC, An Abbvie Company$20
- plus $12 from 1 others
Across 31 payments — averaging $7922.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$246K
What the payments were for
- Food & beverage$26740%
- Education$40460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 8 | $319 |
| Sanofi | 1 | $114 |
| Mirati Therapeutics, Inc. | 1 | $99 |
| Johnson & Johnson | 1 | $85 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $20 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEVTANA$114
How this compares
$670 in reported general payments places this provider in the 35th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 20 | $285,602 |
| Lenalidomide | 14 | $170,919 |
| TabrectaCapmatinib Hydrochloride | 11 | $132,230 |
| ImbruvicaIbrutinib | 13 | $108,853 |
| Abiraterone Acetate | 31 | $38,643 |
| EliquisApixaban | 26 | $26,210 |
| Prednisone | 29 | $411 |
| Dexamethasone | 30 | $367 |
| Acyclovir | 15 | $362 |
| Ondansetron Hcl | 16 | $127 |
| Anastrozole | 15 | $113 |
| Prochlorperazine Maleate | 15 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20 | $108,85313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Hanover
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.